Union Berlin president accuses Bundesliga rivals of not paying their women's teams enough
'Every football club that has a professional team is capable of paying its women's football team appropriately,' Zingler said on Monday in comments reported by dpa news agency.
'When I see and hear that, even in the (women's) Bundesliga with 12 teams, there are only four or five who pay the women professionally, it's a pitiful disgrace in Germany,' Zingler added on the day it was confirmed he will stay on for another term as president to 2029.
Union's own women's team was promoted to the Bundesliga for the first time this season after winning the second division. The Köpenick-based club has invested heavily in women's soccer, particularly since its men's team clinched promotion to the 18-team Bundesliga in 2019.
Zingler also criticized the media for not giving more attention to women's games. He said it was 'simply not right to treat women's football as a disability sport and say we have to run special programs and play highlight games.'
Zingler has been Union's president since 2004, when the men's team was playing at fourth-tier level. He said stability has been key to the club's success.
Union's men reached the Europa Conference League in 2021, the Europa League the following season, and the Champions League in 2023, though that was followed by a brush with relegation. This season, the team clinched Bundesliga survival with four rounds to spare.
Away from the field, Union refurbished its stadium in 2009, added a new main stand in 2013, and established a new training center for youth players last year. This year it plans to start construction on new training facilities for its men's and women's professional teams then turn attention to more stadium development to accommodate more fans.
___
AP soccer: https://apnews.com/hub/soccer
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Hoffenheim target Serbian right back Ognjen Mimović
Yağız Sabuncuoğlu reports that TSG 1899 Hoffenheim are targeting Serbian right back Ognjen Mimović of Fenerbahçe Istanbul. The Turkish journalist already correctly predicted a transfer move involving the Bundesliga club this summer when reporting on a loan out for defender Attila Szalai. Sabuncuoğlu claims that the Sinsheimers have submitted a formal offer for the 20-year-old. Hoffenehim possess an exigent need at the right back position. Valentin Gendrey was meant to fill the slot made vacant by Pavel Kaderabek's departure this summer, but the Frenchman recently succumbed to a serious injury and looks to be out long-term. Mimović only just moved to Fenerbahçe during the January 2025 transfer window on a €6.7m deal from Red Star Belgrade. He was then immediately loaned out to Zenit St. Petersburg. The now twice-capped Serbian international has generated plenty of interests from other clubs. Sabuncuoğlu reports that Antalyaspor are also interested in Mimović. The player himself – having not yet even made an appearance for his new parent club – will obviously wish to take his time making a decision on his future. At present, Mimović maintains an estimated market value of €3.5m. GGFN |
Yahoo
6 minutes ago
- Yahoo
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany. A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company's pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows: Title: EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma Presenter: Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Session Category: Proffered Paper Session Title: Sarcoma Presentation #: 2686O Date and Time: Sunday, 19 October 2025 at 16:30 – 18:00 PM CET Title: Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) –Updates from INSIGHT-003 (IKF614) Presenter: Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany Session Category: Poster Session Title: NSCLC, metastatic Presentation #: 1857P Date and Time: Saturday, 18 October 2025 at 12:00 – 12:45 PM CET Title: TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC Presenter: Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany Session Category: ePoster Session Title: NSCLC, metastatic Presentation #: 2086eTiP Proffered Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives. Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep's website after their presentations. About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
UPI
9 minutes ago
- UPI
Bayer Leverkusen's Granit Xhaka to sign with Sunderland
Veteran midfielder Granit Xhaka (R) is expected to sign a three-year contract with Sunderland. Photo by Ronald Wittek/EPA July 28 (UPI) -- Sunderland agreed to a $23.5 million deal to sign Bayer Leverkusen midfielder Granit Xhaka. He is expected to sign a three-year contract with the club. Sources told Sky Sports, Fabrizio Romano and GiveMeSport about the agreement Monday. Xhaka, 32, joined Leverkusen in 2023. He totaled five goals and seven assists over 66 appearances for the German Bundesliga club. Xhaka registered two goals and seven assists over 33 appearances for Leverkusen in 2024-25, when they finished second in the Bundesliga standings. Leverkusen won the league title in his first season. The veteran midfielder found the net 17 times and logged 24 assists over 225 Premier League appearances for Arsenal. He spent seven seasons with the Gunners. Sunderland is set to return to the Premier League for the first time since 2016-17 after earning promotion from the Championship. The Black Cats went 21-12-13 during their 2024-25 campaign.
